Search results
Results from the WOW.Com Content Network
Online, people claim they get brain zaps after stopping use of drugs like Lexapro (escitalopram), Cymbalta (duloxetine), and Paxil (paroxetine), but they can happen when you stop taking any type ...
Approximately 15–50% of people who suddenly stop an antidepressant develop antidepressant discontinuation syndrome. [7] [2] [3] [4] The condition is generally not serious, [2] though about half of people with symptoms describe them as severe. [4] Many restart antidepressants due to the severity of the symptoms. [4]
If, after a few weeks, it feels like escitalopram isn’t “working,” don’t just stop taking the medication suddenly. Never stop taking the medication or adjust your dosage without speaking ...
Changing your dosage or abruptly stopping your medication could cause you to experience antidepressant withdrawal symptoms like those electric shocks — also known as “brain zaps.” Switching ...
The stopping of antidepressants for example, can lead to antidepressant discontinuation syndrome. With careful physician attention, however, medication prioritization and discontinuation can decrease costs, simplify prescription regimens, decrease risks of adverse drug events and poly-pharmacy, focus therapies where they are most effective, and ...
Escitalopram, sold under the brand names Lexapro and Cipralex, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class. [9] It is mainly used to treat major depressive disorder , [ 9 ] generalized anxiety disorder , [ 9 ] panic disorder , obsessive-compulsive disorder , and social anxiety disorder .
People are more likely to have antidepressant discontinuation symptoms if they suddenly stop taking their medication (as opposed to tapering their doses), have been on the medication for years or ...
Another example of pharmaceutical rebound is a rebound headache from painkillers when the dose is lowered, the medication wears off, or the drug is abruptly discontinued. [ 18 ] In 2022, reports of viral RNA and symptom rebound in people with COVID-19 treated with Paxlovid were published.